Skip to content

NAD+ for Heart Health & Heart Failure: The Evidence

IV NAD+, oral NR, heart failure and blood pressure: what controlled studies measured, which endpoints improved, and what remains unproven.

By Marcus HaleLongevity Research Editor
Updated

5 min read · 10 sources

On this page

NAD+ has a genuinely plausible cardiac story behind it. The heart is one of the most energy-hungry organs in the body, it runs almost entirely on mitochondrial ATP, and failing hearts show disrupted NAD+ metabolism. That biology has launched a wave of marketing — NAD+ IV drips and NMN capsules pitched for "heart health" and "cardiovascular longevity." But the honest gap between that mechanism and proven human benefit is wide. There is a randomized study of IV NAD+ in ischemic heart failure, alongside oral NR and vascular studies — and reading it carefully shows exactly why "promising" and "proven" are not the same word. Here's what the evidence actually supports.

Inflammation findings are condition-specific. Our NAD+ and lupus guide separates an immune-pathway hypothesis from an ongoing clinical trial and proven care.

Affiliate partner

MadeMed

NAD+ injection & nasal spray, in 23 states

See MadeMed

The mechanism: why the heart is an NAD+ story at all

The rationale isn't hype on its face. NAD+ is the central coenzyme of energy metabolism, shuttling electrons through the reactions that let mitochondria make ATP — and the heart's relentless contraction makes it utterly dependent on that supply. In experimental models, NAD+ levels fall in the failing heart, and restoring them protects cardiac function. The most cited demonstration: in a mouse model of dilated cardiomyopathy, nicotinamide riboside (an NAD+ precursor) preserved cardiac function and blunted the disease's progression 1. Reviews of NAD+ metabolism in cardiovascular disease lay out the same throughline — NAD+ decline, mitochondrial dysfunction, and inflammation feed heart disease, making NAD+ repletion a rational target 2.

The cardiac rationale

NAD+

Central energy coenzyme

Mitochondrial ATP

Powers heart contraction

Declines in failing heart

Rationale for repletion

A rational target — but mechanism in mice is not the same as proven benefit in patients.

That's a strong mechanistic case. But mechanism is where cardiology graveyards are full — countless agents that fixed a pathway in mice did nothing, or harm, in people. So the only question that matters is what controlled human trials show.

IV NAD+ in ischemic heart failure

A single-center randomized study tested IV NAD+ in ischemic heart failure. Published online in September 2025 and in a 2026 issue, it is distinct from oral NR research. Researchers enrolled 180 adults with ischemic cardiomyopathy (ejection fraction ≤45%, NYHA class II–III) and randomized them to intravenous NAD+ at 10 mg/day or placebo for 7 days, on top of standard guideline-directed therapy, with follow-up to 6 months 3.

The primary endpoint moved: at one month, left-ventricular ejection fraction was significantly higher in the NAD+ group than placebo (about 45.4% vs 42.4%, p = 0.024) 3. The numerical NYHA differences were not statistically significant, so functional-class improvement should not be presented as an established benefit.

Strength of evidence by claim

  • IV NAD+ → ejection fraction (ischemic heart failure)Moderate evidence

    One small single-center RCT (n=180); significant at 1 month.

  • NR safe + raises NAD+ in heart-failure patientsModerate evidence

    Small randomized safety study; not powered for outcomes.

  • Fewer hospitalizations / lower NT-proBNP / mortalityNone evidence

    Trended only; not statistically significant.

  • Protects the heart in healthy peopleNone evidence

    No human outcome trial; extrapolation from animals.

  • NR and walking performance in PADModerate evidence

    NICE trial showed a six-minute walk benefit; confirmation needed.

  • NR added to exercise lowers daytime blood pressureNone evidence

    The pilot trial did not show superiority on its primary outcome.

Evidence judged on randomized human outcomes. Harder endpoints remain unproven.

But read the rest of the numbers, because this is where honesty matters. The reduction in NT-proBNP (a key heart-failure blood marker) was only a trend and did not reach statistical significance (p = 0.102) 3. The drop in 6-month major adverse cardiac events and in heart-failure hospitalizations also only trended lower without reaching significance (roughly 14.6% vs 24.7% for the composite, p = 0.089) 3. In plain terms: the trial showed a modest, real improvement in a heart-function measurement, but it did not prove NAD+ keeps people with heart failure out of the hospital or alive longer. Those are the outcomes patients actually care about, and they remain unproven.

It is a single-center trial using a specific low-dose intravenous course — not an oral supplement, and not the kind of large, multi-center, hard-outcome trial that changes guidelines. It is a reason for cautious optimism and more research, not a green light to treat heart failure with NAD+.

What the precursor (NR) trials add

The other strand of human evidence comes from nicotinamide riboside (NR) in heart failure. A randomized trial gave NR (1,000 mg twice daily) for 12 weeks to people with heart failure with reduced ejection fraction; it roughly doubled whole-blood NAD+ and was generally tolerated during the monitored study 4. Encouragingly, the rise in NAD+ correlated with improved mitochondrial respiration in blood cells and lower expression of the NLRP3 inflammasome — a mechanistic hint that the pathway engages in humans 4. But the authors are explicit that the study was a safety and tolerability trial, not powered for clinical outcomes 4. An earlier open-label pharmacokinetic study involved healthy volunteers, not heart-failure patients 5. It cannot be counted as a second heart-failure efficacy trial. The small human NR study supports feasibility and short-term tolerability — it does not establish that NR makes failing hearts work better in ways patients feel.

Walking performance and blood pressure

Cardiovascular research is not confined to heart failure. In the NICE trial, 90 people with peripheral artery disease received NR, NR plus resveratrol or placebo for six months. NR improved six-minute walking distance versus placebo; adding resveratrol did not add benefit 9. This is a functional result in a specific disease population, not proof that NR prevents heart attacks or improves general wellness.

A 2025 pilot enrolled 54 older adults with elevated blood pressure. NR plus supervised walking did not improve the primary daytime systolic-pressure outcome more than placebo plus walking. Exploratory nighttime findings in a subgroup without blood-pressure medication need confirmation 10. They should not replace the negative primary comparison in a summary or advertisement.

Where the marketing outruns the evidence

This is the crucial divide for anyone reading drip-clinic or supplement copy. Heart-failure evidence includes: a single small RCT showing an ejection-fraction improvement with IV NAD+ in ischemic heart failure 3, plus safety/mechanism data for NR in heart failure 4, plus protective findings in animals 1. The cited studies do not establish prevention of heart attacks or lower cardiovascular mortality. The PAD and hypertension trials also show why it is inaccurate to describe all vascular evidence as heart-failure research. Claims that NMN or NAD+ IVs are "cardioprotective" for healthy adults are extrapolation from animals and mechanism — the kind of leap that, in cardiology, frequently fails to pan out. NMN reliably raises blood NAD+ in people 6 and slows decline in aged mice 7, but neither is a cardiovascular outcome.

If you have heart disease, the practical bottom line is blunt: NAD+ is not a substitute for guideline-directed heart-failure therapy, and even in the one positive trial it was given on top of that therapy 3. Talk to a cardiologist before adding anything.

Bottom line

The heart is a legitimate NAD+ target, and a single-center IV study reported a better ejection-fraction result at one month 3. That's a real milestone — but it's one small, short, single-center trial whose harder endpoints (NT-proBNP, hospitalizations, mortality) only trended and were not proven 3. The small NR study supports monitored tolerability and target engagement, without establishing clinical benefit in heart failure 4. The PAD walking result and the negative primary blood-pressure result add important context 910, but neither establishes routine cardiovascular prevention in healthy adults. Treat it as a promising research direction, not a proven cardiac therapy. For the broader evidence picture, see our pillar guide to NAD+ therapy; for the related questions of whether NAD+ delivers more energy or slows aging; and for where products land overall, the best NAD+ supplements.

Frequently asked questions

Is there real evidence NAD+ helps heart failure?

A single-center study of 180 people with ischemic heart failure found a better ejection fraction at one month after seven days of low-dose IV NAD+ added to standard therapy. NT-proBNP, hospitalization and functional-class comparisons did not establish significant benefits. This does not prove better survival or validate commercial wellness protocols.

Can NAD+ or NMN protect a healthy heart?

The cited studies do not establish prevention of heart attacks or cardiovascular death in healthy people. Research includes heart failure, PAD and hypertension, and their different outcomes should not be generalized to everyone.

Is nicotinamide riboside (NR) safe for people with heart failure?

A small monitored trial found NR was tolerated over 12 weeks and raised blood NAD+. That supports feasibility under study conditions, not a blanket safety assurance or established clinical benefit for everyone with heart failure.

Should I take NAD+ instead of my heart medications?

No. Even in the one positive trial, NAD+ was given on top of guideline-directed heart-failure therapy, not instead of it. NAD+ is not a proven substitute for established cardiac treatment. If you have heart disease, talk to a cardiologist before adding any supplement or IV.

References

  1. Diguet N, Trammell SAJ, Tannous C, et al. (2018). Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy. Circulation. https://pubmed.ncbi.nlm.nih.gov/29217642/
  2. Li H, Wang Y, et al. (2025). The Role of NAD+ Metabolism in Cardiovascular Diseases: Mechanisms and Prospects. American Journal of Cardiovascular Drugs. https://pubmed.ncbi.nlm.nih.gov/39707143/
  3. Yu X, et al. (2026). Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial. American Journal of Cardiovascular Drugs. https://pubmed.ncbi.nlm.nih.gov/40954388/
  4. Wang DD, Airhart SE, Zhou B, et al. (2022). Safety and Tolerability of Nicotinamide Riboside in Heart Failure With Reduced Ejection Fraction. JACC: Basic to Translational Science. https://pubmed.ncbi.nlm.nih.gov/36644285/
  5. Airhart SE, Shireman LM, Risler LJ, et al. (2017). An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One. https://pubmed.ncbi.nlm.nih.gov/29211728/
  6. Yi L, Maier AB, Tao R, et al. (2023). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. https://pubmed.ncbi.nlm.nih.gov/36482258/
  7. Mills KF, Yoshida S, Stein LR, et al. (2016). Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metabolism. https://pubmed.ncbi.nlm.nih.gov/28068222/
  8. Podyacheva E, Toropova Y (2022). Intravenous Nicotinamide Riboside Administration Has a Cardioprotective Effect in Chronic Doxorubicin-Induced Cardiomyopathy. International Journal of Molecular Sciences. https://pubmed.ncbi.nlm.nih.gov/36361882/
  9. McDermott MM, Martens CR, Domanchuk KJ, et al. (2024). Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nature Communications. https://pubmed.ncbi.nlm.nih.gov/38871717/
  10. Lin Y, Zeidan RS, Lapierre-Nguyen S, et al. (2025). Nicotinamide riboside combined with exercise to treat hypertension in middle-aged and older adults: a pilot randomized clinical trial. GeroScience. https://pubmed.ncbi.nlm.nih.gov/40770531/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.